Publications by authors named "Nicholas M Valiante"

Claim this Profile
I
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.
Joseph R Francica, Daniel E Zak, Caitlyn Linde, Emilio Siena, Carrie Johnson, Nicholas M Valiante

Blood Adv· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.
Cecilia Buonsanti, Cristiana Balocchi, Carole Harfouche, Federica Corrente, Luisa Galli Stampino, Nicholas M Valiante

Sci Rep· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
Alex Cortez, Yongkai Li, Andrew T Miller, Xiaoyue Zhang, Kathy Yue, Nicholas M Valiante

J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Melissa Santone, Susanna Aprea, Tom Y H Wu, Michael P Cooke, M Lamine Mbow, Nicholas M Valiante

Hum Vaccin Immunother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.
Joseph R Francica, Zizhang Sheng, Zhenhai Zhang, Yoshiaki Nishimura, Masashi Shingai, Nicholas M Valiante

Nat Commun· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.
Fabio Bagnoli, Maria Rita Fontana, Elisabetta Soldaini, Ravi P N Mishra, Luigi Fiaschi, Nicholas M Valiante

Proc Natl Acad Sci U S A· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cationic nanoemulsion for the delivery of next-generation RNA vaccines.
Luis A Brito, Michelle Chan, Christine A Shaw, Armin Hekele, Thomas Carsillo, Nicholas M Valiante

Mol Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR inhibition improves immune function in the elderly.
Joan B Mannick, Giuseppe Del Giudice, Maria Lattanzi, Nicholas M Valiante, Jens Praestgaard

Sci Transl Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of small molecules as vaccine adjuvants.
Tom Y-H Wu, Manmohan Singh, Andrew T Miller, Ennio De Gregorio, Francesco Doro, Nicholas M Valiante

Sci Transl Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.
David I Bernstein, Rhonda D Cardin, Fernando J Bravo, Julie Earwood, Jennifer R Clark, Nicholas M Valiante

Antivir Chem Chemother· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.
Christine A Shaw, Jean-Rene Galarneau, Kathryn E Bowenkamp, Kurt A Swanson, Gene A Palmer, Nicholas M Valiante

Vaccine· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonviral delivery of self-amplifying RNA vaccines.
Andrew J Geall, Ayush Verma, Gillis R Otten, Christine A Shaw, Armin Hekele, Nicholas M Valiante

Proc Natl Acad Sci U S A· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.
Carla Russo, Ivan Cornella-Taracido, Luisa Galli-Stampino, Rishi Jain, Edmund Harrington, Nicholas M Valiante

Blood· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.
Carlo Iavarone, Katrin Ramsauer, Andriy V Kubarenko, Jason C Debasitis, Igor Leykin, Nicholas M Valiante

J Immunol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New adjuvants for human vaccines.
M Lamine Mbow, Ennio De Gregorio, Nicholas M Valiante, Rino Rappuoli

Curr Opin Immunol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection.
Stefania Crotta, Michela Brazzoli, Diego Piccioli, Nicholas M Valiante, Andreas Wack

J Hepatol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation.
Diego Piccioli, Chiara Sammicheli, Simona Tavarini, Sandra Nuti, Elisabetta Frigimelica, Nicholas M Valiante

Blood· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.
Monia Draghi, Achal Pashine, Bharati Sanjanwala, Ketevan Gendzekhadze, Claudia Cantoni, Nicholas M Valiante

J Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells.
Stefania Crotta, Vanessa Ronconi, Cristina Ulivieri, Cosima T Baldari, Nicholas M Valiante

Eur J Immunol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the innate immune response with improved vaccine adjuvants.
Achal Pashine, Nicholas M Valiante, Jeffrey B Ulmer

Nat Med· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I.
Monia Draghi, Nobuyo Yawata, Michael Gleimer, Makoto Yawata, Nicholas M Valiante

Blood· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate immunity and biodefence vaccines.
Nicholas M Valiante, Derek T O'Hagan, Jeffrey B Ulmer

Cell Microbiol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the discovery and delivery of vaccine adjuvants.
Derek T O'Hagan, Nicholas M Valiante

Nat Rev Drug Discov· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different profile of CD8+ effector T cells induced in Der p 1-allergic and naïve mice by DNA vaccination.
Monia Draghi, Elizabeth R Jarman, Renata Grifantini, Luisa Galli-Stampino, Jonathan R Lamb, Nicholas M Valiante

Eur J Immunol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells.
Diego Piccioli, Silverio Sbrana, Emiliano Melandri, Nicholas M Valiante

J Exp Med· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis